By Najat Kantouar

GSK said that it had positive results from phase III trials of depemokimab, aimed at assessing the drug's efficacy and safety in adults and adolescents with severe asthma.

The British pharmaceutical company said Tuesday that the treatment has the potential to be the first approved ultra-long-acting biologic with a six-month dosing schedule for severe asthma, and could support millions of patients with severe asthma.

Depemokimab is currently not approved anywhere in the world, the company said.

Write to Najat Kantouar at

(END) Dow Jones Newswires

05-21-24 0232ET